Buyback yield (TTM)
1.56%
Shareholder yield (TTM)
1.56%
5Y share count change
-7.3%
Buyback spend (TTM)
$724.90M
Cumulative buybacks
$11.08B
Key takeaways
- Edwards Lifesciences (EW) repurchased about $724.90M of stock over the trailing twelve months.
- Diluted share count is down 7.3% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 4.44× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +7.4% per year over the latest 5-year window.
- TTM repurchases used about 67% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Edwards Lifesciences (EW)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Edwards Lifesciences (EW)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Edwards Lifesciences (EW)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Edwards Lifesciences (EW)
Latest: $893.40M
Overview
Edwards Lifesciences (EW) most recent annual buyback spend stands at $893.40M (2025) – declined 22.9% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Edwards Lifesciences buyback spend compounded at +7.4% per year, with mixed annual results across the window.
Edwards Lifesciences buyback spend peaked at $1.73B in 2022; the latest annual figure is $893.40M in 2025 (48.3% below peak).
2022 marks the peak buyback spend at $1.73B, with the historical low of $0.00 recorded in 1999.
Edwards Lifesciences Buyback Spend 2025: $893.40M
Edwards Lifesciences buyback spend in 2025 was $893.40M, declined 22.9% below 2024.
Edwards Lifesciences Buyback Spend 2024: $1.16B
2024's buyback spend for Edwards Lifesciences came in at $1.16B, surged 31.8% from 2023.
Edwards Lifesciences Buyback Spend 2023: $879.60M
Edwards Lifesciences posted buyback spend of $879.60M in 2023, plunged 49.1% below 2022.
Edwards Lifesciences Buyback Spend 2022: $1.73B
In 2022, Edwards Lifesciences reported buyback spend of $1.73B, surged 236.8% from 2021. This figure represents the highest annual value in the available history.
Edwards Lifesciences Buyback Spend 2021: $512.80M
Edwards Lifesciences buyback spend in 2021 was $512.80M.
See more financial history for Edwards Lifesciences (EW).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $893.40M | $158.10M | $735.30M | 1.81% | 0.59B | -2.3% | |
| 2024 | $1.16B | $162.30M | $997.10M | 2.66% | 0.60B | -1.7% | |
| 2023 | $879.60M | $139.40M | $740.20M | 1.91% | 0.61B | -2.4% | |
| 2022 | $1.73B | $126.80M | $1.60B | 3.78% | 0.62B | -1.1% | |
| 2021 | $512.80M | $109.30M | $403.50M | 0.63% | 0.63B | -0.1% | |
| 2020 | $625.40M | $92.60M | $532.80M | 1.10% | 0.63B | -0.7% | |
| 2019 | $263.30M | $81.30M | $182.00M | 0.54% | 0.64B | -0.7% | |
| 2018 | $795.50M | $71.00M | $724.50M | 2.50% | 0.64B | -1.1% | |
| 2017 | $763.30M | $61.60M | $701.70M | 3.21% | 0.65B | -0.9% | |
| 2016 | $662.30M | $56.90M | $605.40M | 3.31% | 0.65B | -1.1% | |
| 2015 | $280.10M | $49.90M | $230.20M | 1.64% | 0.66B | +1.5% | |
| 2014 | $300.90M | $48.30M | $252.60M | 2.20% | 0.65B | -4.7% | |
| 2013 | $496.90M | $47.40M | $449.50M | 6.92% | 0.68B | -3.8% | |
| 2012 | $344.10M | $42.10M | $302.00M | 3.32% | 0.71B | -0.9% | |
| 2011 | $303.40M | $35.00M | $268.40M | 3.76% | 0.72B | +0.2% | |
| 2010 | $200.00M | $29.30M | $170.70M | 2.18% | 0.72B | +1.5% | |
| 2009 | $95.50M | $28.30M | $67.20M | 1.95% | 0.70B | -1.5% | |
| 2008 | $306.50M | $28.70M | $277.80M | 10.00% | 0.72B | -4.9% | |
| 2007 | $130.90M | $27.70M | $103.20M | 5.02% | 0.75B | -1.9% | |
| 2006 | $145.90M | $26.60M | $119.30M | 5.38% | 0.77B | +2.6% | |
| 2005 | $53.50M | $0.00 | $53.50M | 2.16% | 0.75B | +0.5% | |
| 2004 | $59.10M | $0.00 | $59.10M | 2.40% | 0.74B | +1.5% | |
| 2003 | $49.40M | $0.00 | $49.40M | 2.78% | 0.73B | -0.3% | |
| 2002 | $30.80M | $0.00 | $30.80M | 2.06% | 0.74B | +4.1% | |
| 2001 | $0.00 | $0.00 | $0.00 | — | 0.71B | +1.4% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 0.70B | 0.0% | |
| 1999 | $0.00 | $0.00 | $0.00 | — | 0.70B | — |
- 2025$893.40M
- 2024$1.16B
- 2023$879.60M
- 2022$1.73B
- 2021$512.80M
- 2020$625.40M
- 2019$263.30M
- 2018$795.50M
- 2017$763.30M
- 2016$662.30M
- 2015$280.10M
- 2014$300.90M
- 2013$496.90M
- 2012$344.10M
- 2011$303.40M
- 2010$200.00M
- 2009$95.50M
- 2008$306.50M
- 2007$130.90M
- 2006$145.90M
- 2005$53.50M
- 2004$59.10M
- 2003$49.40M
- 2002$30.80M
- 2001$0.00
- 2000$0.00
- 1999$0.00
Buybacks vs stock-based compensation for Edwards Lifesciences (EW)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 4.44×.
Buybacks vs dividends (share of cash returned) for Edwards Lifesciences (EW)
How Edwards Lifesciences splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Edwards Lifesciences, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.09B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation